scholarly journals Global Pandemic Trends of COVID-19 in 2020

Author(s):  
Hai-Zhen Chen ◽  
Bo Cai ◽  
Jian-Guo Chen

Abstract Background: The novel coronavirus pneumonia (COVID-19) has been global threaten to public health. This paper provides perspective to the decision-making for public health control of the pandemic or the spread of epidemic.Methods: According to the WHO global reported database, we developed and used the number of cumulative cases, and the number of cumulative deaths to calculate and analyze rates of incidence, mortality, and fatality by country, with respect to the 30 highest outbreak (Top 30) countries.Results: As of December 31, 2020, of the global population of 7.585 billion, the cumulative number of reported cases was 81,475,053, and the cumulative number of deaths was 1,798,050. The incidence rate of COVID-19 was 1074.13 per 100,000 population, the mortality rate was 23.70 per 100,000, and the case fatality rate was 2.21%. Among the Top 30 countries, the five countries with the highest number of reported cumulative cases were, in rank, the United States (19,346,790 cases), India (10,266,674), Brazil (7,563,551), Russia (3,159,297) and France (2,556,708), and the five countries with the highest number of cumulative deaths were the United States (335,789 cases), Brazil (192,681), India (148,738), Mexico (123,845) and Italy (73,604). Globally, the countries with the highest incidence rate were, in rank, Andorra, Luxembourg, Montenegro, San Marino, and Czechia; the countries with the highest mortality rate were, in rank, San Marino, Belgium, Slovenia, Italy, and North Macedonia. The highest fatality rate was found in Yemen, Mexico, Montserrat, Isle of Man, and Ecuador, respectively. In China, 96,673 cases of COVID-19 and 4788 deaths were reported in 2020, ranking the 78th and the 43rd, respectively, in the world. The incidence rate and mortality rate were 6.90/105 and 0.34/105, respectively, ranking 207th and 188th in the world. The case fatality rate was 4.95%, ranking 11th in the world.Conclusions: The COVID-19 prevalence is still on the rise, and the turning points of incidence and mortality are not yet forecasted. Personal protection, anti-epidemic measures and efforts from public health personnel, medical professionals, biotechnology R&D personnel, effectiveness of the vaccination programs and the governments, are the important factors to determine the future prevalence of this coronavirus disease.

PEDIATRICS ◽  
1950 ◽  
Vol 5 (5) ◽  
pp. 840-852
Author(s):  
JEROME L. KOHN ◽  
ALFRED E. FISCHER ◽  
HERBERT H. MARKS

Analysis of data on patients with pertussis during 1942-1946 obtained by means of a questionnaire from communicable disease hospitals and from health officers in a number of cities in the United States and Canada showed these results: Case fatality rates of patients admitted to hospitals for treatment have declined substantially in the period under review. This decline is general, both among infants under one year of age and among older children. In 1946, the case fatality rate of the infants hospitalized for the disease was 5.0% in those cities for which data for at least four years were available. This may be compared with the rate of 7.8% in 1942 and 11.1% in 1943. At ages one year and over, the rate was only 1.3% in 1946, as compared with 1.7% in 1942 and 3.7% in 1943. The rates in the hospitals with larger experiences were generally more favorable than in hospitals with smaller experiences. Despite the incomplete reporting of pertussis, which results in exaggerating the case fatality rate for the general population, the level of these rates in the community as a whole was lower than for hospitalized cases. This reflects the higher proportion of the severer cases in the hospitalized group. Indications are that in many places hospitalization is limited more and more to severe cases. Progress in the management of pertussis, especially of the severer cases admitted to hospitals, is believed to be the chief factor in the decline in case fatality of pertussis. A request contained in the questionnaire for an opinion on the severity of pertussis during the period studied elicited few replies, and these replies showed a division of opinion on the matter. It appears unlikely that there has been much of any change in the severity of the disease.


2015 ◽  
Vol 144 (1) ◽  
pp. 198-206 ◽  
Author(s):  
R.-F. WANG ◽  
S.-H. SHEN ◽  
A. M.-F. YEN ◽  
T.-L. WANG ◽  
T.-N. JANG ◽  
...  

SUMMARYInformation is lacking on the integrated evaluation of mortality rates in healthcare-associated infections (HAIs). Our aim was to differentiate the risk factors responsible for the incidence from those for the case-fatality rates in association with HAIs. We therefore examined the time trends of both incidence and case-fatality rates over a 20-year period at a tertiary-care teaching medical centre in Taiwan and the mortality rate was expressed as the product of the incidence rate and the case-fatality rate. During the study period the overall mortality rate fell from 0·46 to 0·32 deaths/1000 patient-days and the incidence rate fell from 3·41 to 2·31/1000 patient-days, but the case-fatality rate increased marginally from 13·5% to 14·0%. The independent risk factors associated with incidence of HAIs were age, gender, infection site, admission type, and department of hospitalization. Significant prognostic factors for HAI case-fatality were age, infection site, intensive care, and clinical department. We conclude that the decreasing trend for the HAI mortality rate was accompanied by a significant decline in the incidence rate and this was offset by a slightly increasing trend in the case-fatality rate. This deconstruction approach could provide further insights into the underlying complex causes of mortality for HAIs.


2009 ◽  
Vol 30 (11) ◽  
pp. 1036-1044 ◽  
Author(s):  
Omar M. AL-Rawajfah ◽  
Frank Stetzer ◽  
Jeanne Beauchamp Hewitt

Background.Although many studies have examined nosocomial bloodstream infection (BSI), US national estimates of incidence and case-fatality rates have seldom been reported.Objective.The purposes of this study were to generate US national estimates of the incidence and severity of nosocomial BSI and to identify risk factors for nosocomial BSI among adults hospitalized in the United States on the basis of a national probability sample.Methods.This cross-sectional study used the US Nationwide Inpatient Sample for the year 2003 to estimate the incidence and case-fatality rate associated with nosocomial BSI in the total US population. Cases of nosocomial BSI were defined by using 1 or more International Classification of Diseases, 9th Revision, Clinical Modification codes in the secondary field(s) that corresponded to BSIs that occurred at least 48 hours after admission. The comparison group consisted of all patients without BSI codes in their NIS records. Weighted data were used to generate US national estimates of nosocomial BSIs. Logistic regression was used to identify independent risk factors for nosocomial BSI.Results.The US national estimated incidence of nosocomial BSI was 21.6 cases per 1,000 admissions, while the estimated case-fatality rate was 20.6%. Seven of the 10 leading causes of hospital admissions associated with nosocomial BSI were infection related. We estimate that 541,081 patients would have acquired a nosocomial BSI in 2003, and of these, 111,427 would have died. The final multivariate model consisted of the following risk factors: central venous catheter use (odds ratio [OR], 4.76), other infections (OR, 4.61), receipt of mechanical ventilation (OR, 4.97), trauma (OR, 1.98), hemodialysis (OR, 4.83), and malnutrition (OR, 2.50). The total maximum rescaled R2 was 0.22.Conclusions.The Nationwide Inpatient Sample was useful for estimating national incidence and case-fatality rates, as well as examining independent predictors of nosocomial BSI.


2021 ◽  
Author(s):  
Moslem Taheri Soodejani ◽  
Ali Akbar Haghdoost ◽  
Mohammad Hassan Lotfi ◽  
Marzieh Mahmudimanesh ◽  
Seyyed Mohammad Tabatabaei

Abstract Background: The present study is designed to predict the global adjusted values for mortality rate and case fatality rate of COVID-19 around the world. Methods: This research was conducted at the ecological level using data from 100 countries which were chosen randomly. The adjusted values were predicted using beta regression considering predictive factors such as total expenditure on health per capita, expenditure on health as a percentage of GDP, life expectancy and the percentage of the population aged over 65 years, hospital beds (per 1000 population), physicians (per 1000 population), nurses (per 1000 population), prevalence of smoking, prevalence of diabetes mellitus, and number of confirmed tests in each country. In the end, applying Monte Carlo simulation, the adjusted values of mortality rate and case fatality rate for the whole world were estimated.Results: The results of this study showed that two factors including percentage of population ages 65 and above (P=0.03) and Total expenditure on health as % of GDP (P = 0.04) had a statistically significant relationship with the case fatality rate. Moreover, there was a statistically significant relationship between the mortality rate and life expectancy (P = 0.02), total expenditure on health per capita (P < 0.001), nurses (Per 1000 Population) (P=0.04), and the prevalence of Diabetes Mellitus (P=0.04). The mortality rate and case fatality rate for the whole world were estimated to be 0.000001 and 0.026, respectively.Conclusion: It seems that what can cause global concern is not the case fatality rate of the disease, but its mortality rate, which is directly related to the health status of a community. The worse the health status of a community, the greater the number of infected people likely to be there, that ultimately increases the mortality rate of the disease in the community.


2011 ◽  
Vol 21 (Supp 1) ◽  
pp. S1-S2 ◽  
Author(s):  
Andrés Poveda

Ovarian cancer is the second most common gynecological cancer, representing 5% of all cancers in women. It has the highest case-fatality rate of all gynecological malignancies. In the European Union, there are approximately 48,000 new cases of ovarian cancer and 31,000 deaths per year. Similarly, in the United States, there are approximately 25,500 new cases per year, with 16,000 deaths associated.


Author(s):  
Eldhose Iype ◽  
Sadhya Gulati

AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are rising rapidly every day in the world, causing the disease COVID-19 with around 2 million people infected and more than 100,000 people died so far, in more than 200 countries. One of the baffling aspects of this pandemic is the asymmetric increase in cases and case fatality rate (CFR) among countries. We analyze the time series of the infection and fatality numbers and found two interesting aspects. Firstly, the rate of spread in a region is directly connected to the population density of the region where the virus is spreading. For example, the high rate of increase in cases in the United States of America (USA) is related to the high population density of New York City. This is shown by scaling the cumulative number of cases with a measure of the population density of the affected region in countries such as Italy, Spain, Germany, and the USA and we see that the curves are coinciding. Secondly, we analyzed the CFR number as a function of the number of days, since the first death, and we found that there are two clear categories among countries: one category with high CFR numbers (around 10%) and the other category with low CFR numbers (2% to 4%). When we analyzed the results, we see that countries with lower CFR numbers more or less tend to have implemented active control measures such as aggressive testing, tracking down possible infections, effective quarantine measures, etc. Moreover, we did not see any convincing correlation between mortality rates and the median age of the population.


2020 ◽  
Vol 18 (2) ◽  
pp. 87-89
Author(s):  
George W. Contreras, DrPH(c), MEP, MPH, MS, CEM

As of March 2020, we are almost at the three-month mark of COVID-19 with 90,663 reported cases worldwide and 3,124 reported deaths spread over six continents and 67 countries. As of March 3, 2020, the United States announced its six COVID-19-related deaths with 103 confirmed cases spread throughout fourteen states.1 It is important to note, however, that even as the number of reported cases and deaths continue to increase, the COVID-19 overall case fatality rate thus far stands at 3.4 percent. It is important to keep in mind that case fatality rates will also vary by age group and geographic areas. Government leaders and health experts have repeatedly mentioned that it is expected that COVID-19 cases would increase and that it would inevitably reach the United States. I would go even a step further to predict that there will be more confirmed cases and deaths in the United States as well as other parts of the world. Unfortunately and inevitably, by the time this editorial is published, the number of reported cases and deaths will have increased worldwide. If there is one thing to take from all of this information is that we are just at the beginning of the disease progression and more people will get infected and some additional people will also die. As a society, we need not be alarmed simply because it is a novel infectious disease. In the twentieth century, the world has experienced several novel diseases and even pandemic-level diseases. The recent CDC announcement that COVID-19 may reach pandemic levels is not only expected but also scientifically accurate when it comes to normal disease progression. Such announcements should not surprise the public and it should also not instill panic. What the world and the United States need to do is get better prepared. I understand that the fear of the unknown can be daunting but we need to recall that we (the US and the world) have been through similar experiences and survived.


2020 ◽  
Vol 44 ◽  
Author(s):  

Notified cases of COVID-19 and associated deaths reported to the National Notifiable Diseases Surveillance System (NNDSS) to 7 June 2020. Confirmed cases in Australia notified up to 7 June 2020: notifications = 7,277; deaths = 102. Over the past fortnightly reporting period, the number of new cases in all jurisdictions continues to decline, or remain very low, and testing rates continue to be high across all jurisdictions, with the positivity rate remaining very low at less than 0.1%. The incidence of COVID-19 has markedly reduced since a peak in mid-March. A combination of early case identification, physical distancing, public health measures and a reduction in international travel have been effective in slowing the spread of disease in Australia. Of the 147 cases notified between 25 May and 7 June, 63% acquired their infection overseas. The proportion of cases locally acquired has dropped substantially to 28% of new cases this period compared with 50% and greater observed since 30 March 2020. Of the cases considered to be locally-acquired over this period, most were associated with contacts of confirmed cases or were associated with known outbreaks. A small proportion of overall cases have experienced severe disease, requiring hospitalisation or intensive care with some fatalities. The crude case fatality rate amongst Australian cases is 1.4%. People who are older and have one or more comorbidities are more likely to experience severe disease. The highest rate of COVID-19 continues to be among people aged 65–79 years. Three-quarters of all cases in this age group have been associated with overseas travel, including several outbreaks linked to cruise ships. The lowest rate of disease is in children under 18, a pattern reflected in international reports. Internationally, as of 7 June 2020, the largest numbers of both cases and deaths have been reported in the United States. Of the confirmed cases reported globally, the case fatality rate is approximately 5.8%. Countries in South America are seeing rapid growth in case numbers, while the United States is seeing a steady decline in its daily new case numbers. Case numbers in Europe remain relatively steady, with several countries in Eastern Europe experiencing rapid growth. In the South East Asia region, India and Bangladesh are seeing accelerating epidemics, compounded by the recovery from Cyclone Amphan. Reported cases are increasing in Africa, although the numbers are much smaller. In the Pacific there are few new cases reported daily.


Sign in / Sign up

Export Citation Format

Share Document